Myeloproliferative Neoplasms
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and Without Red Blood Cell-Transfusion Dependence
CLGN 1917
View full trial information
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Myelodysplastic Syndrome (MDS)
A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
MEDI 1917
View full trial information
Essential Thrombocythemia, Myelofibrosis
Prospective, longitudinal, non-interventional study of disease burden and treatment of patients with low-risk myelofibrosis (mf) or high-risk essential thrombocythemia (ET) or et patients receiving et-directed therapy
INCT 1Z16
View full trial information
Lymphoma, Diffuse Large B Cell, Lymphoma, Non – Hodgkin
A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination with Rituximab in Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin’s Lymphoma
DBPI 1415
View full trial information
Leukemia, Acute Myeloid (AML), Leukemia, Chronic Myelomonocytic (CMML), Myelodysplastic Syndrome (MDS)
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
H3BM 1916
View full trial information
Search our Cancer Clinical Trials Database for a full listing of all open and accruing studies.
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy